Pectin/Kollicoat SR30D isolated films for colonic delivery [I]: A comparison of normal and colitis-induced models to assess the efficiency of microbially triggered drug delivery

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 2, 2009, Pages 167-176

  Wei, He ^a,d   Li Fang, Fan ^a,b   Yong Zhen, Chang ^c   Bai, Xiang ^a   Qing, Du ^a   Min, Bai ^d   Feng, Wang ^e   Min, Qing ^f   De Ying, Cao ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Hebei Yiling Pharmaceutical Group   (China)

^c XingTai Medical College   (China)

^d CSPC Pharmaceutical Technology Co Ltd   (China)

^e CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^f Liuzhou Worker Hospital   (China)

Author keywords

Colonic drug delivery; Degradation; Kollicoat sr30d; Pectin; Permeability; Rat

Indexed keywords

FLUOROURACIL; KOLLICOAT SR 30D; PECTIN; POLYVINYL ACETATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLITIS; CONTROLLED STUDY; DEGRADATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; FILM COATING; INTESTINE FLUID; NONHUMAN; RAT; SIMULATION;

EID: 59049100703     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.02.0005     Document Type: Article

References (70)

1. Jain A et al. Perspectives of biodegradable natural polysaccharides for site-specific drug delivery to the colon. J Pharm Pharm Sci 2007; 10: 86-128.
2. Gorbach SL. Intestinal flora. Gastroenterology 1971; 60: 1110-1129.
3. Cummings JH, Macfarlane GT. The control and consequences of bacterial fermentation in the human colon. J Appl Bacteriol 1991; 70: 443-459.
4. Yang L. Biorelevant dissolution testing of colon-specific delivery systems activated by colonic microflora. J Control Release 2008; 125: 77-86.
5. Cummings JH, Englyst HN. Fermentation in the human large intestine and the available substrates. Am J Clin Nutr 1987; 45: 1243-1255.
6. Rubinstein A. Microbially controlled drug delivery to the colon. Biopharm Drug Dispos 1990; 11: 465-475.
7. Hawksworth G et al. Intestinal bacteria and hydrolysis of glycosidic bonds. J Med Microbiol 1971; 4: 451-459.
8. Scheline RR. Metabolism of foreign compounds by gastrointestinal micro-organisms. Pharmacol Rev 1973; 25: 451-523.
9. Englyst HN et al. Polysaccharide breakdown by mixed populations of human fecal bacteria. FEMS Microbiol Ecol 1987; 95: 163-171.
10. Larsen C et al. Macromolecular prodrugs. XVI. Colontargeted delivery - comparison of the rate of release of naproxen from dextran ester prodrugs in homogenates of various segments of the pig gastrointestinal (GI) tract. Pharm Res 1989; 6: 995-999.
11. Macleod GS et al. Studies on the physical properties of mixed pectin/ethylcellulose films intended for colonic drug delivery. Int J Pharm 1997; 157: 53-60.
12. Milojevic S et al. Amylose as coating for drug delivery to the colon: preparation and in vitro evaluation using 5-aminosal-icylic acid pellets. J Control Release 1996a; 38: 75-84.
13. Milojevic S et al. Amylose as coating for drug delivery to the colon: preparation and in vitro evaluation using glucose pellets. J Control Release 1996; 38: 85-94.
14. Wilson PJ, Basit AW. Exploiting gastrointestinal bacteria to target drugs to the colon: an in vitro study using amylose coated tablets. Int J Pharm 2005; 300: 89-94.
15. 13C] glucose microspheres as a model for drug delivery to the colon. J Control Release 1996; 40: 123-131.
16. Tuleu C et al. Colonic delivery of 4-aminosalicylic acid using amylose-ethylcellulose-coated hydroxypropylmethyl- cellulosecapsules. Aliment/Pharmacol ther 2002; 16: 1771-1779.
17. Basit AW et al. The use of formulation technology to assess regional gastrointestinal drug absorption in humans. Eur J Pharm Sci 2004; 21: 179-189.
18. Chourasia MK, Jain SK. Polysaccharides for colon targeted drug delivery. Drug Deliv 2004; 11: 129-148.
19. Wakerly Z et al. Pectin/ethylcellulose film coating formulations for colonic drug delivery. Pharm Res 1996; 13: 1210-1212.
20. Semde R et al. Leaching of pectin from mixed pectin/insoluble polymer films intended for colonic drug delivery. Int J Pharm 1998; 174: 233-241.
21. Liu LS et al. Pectin-based systems for colon-specific drug delivery via oral route. Biomaterials 2003; 24: 3333-3343.
22. He W et al. In-vitro and in-vivo studies of pectin/ethylcellulose film-coated pellets of 5-fluorouracil for colonic targeting. J Pharm Pharmacol 2008; 60: 35-44.
23. Dashevsky A et al. Physicochemical and release properties of pellets coated with Kollicoat SR 30 D, a new aqueous polyvinyl acetate dispersion for extended release. Int J Pharm 2005; 290: 15-23.
24. Kolter K, Ruchatz F. Kollicoat SR 30D - a new sustained-release excipient. Proc Int Symp Control Release Bioact Mater 1999; 26: 6311.
25. Shao ZJ et al. Drug release from Kollicoat SR 30D-coated nonpareil beads: evaluation of coating level, plasticizer type, and curing condition. AAPS PharmSciTech 2002; 3: E15.
26. Sinha VR, Kumria R. Microbially triggered drug delivery to the colon. Eur J Pharm Sci 2003; 18: 3-18.
27. Swidsinski A et al. Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology 2008; 135: 568-579.
28. Rowlanmd IR. Factors affecting metabolic activity of the intestinal microflora. Drug Metab Rev 1988; 19: 243-261.
29. Carrette O et al. Bacterial enzymes used for colon-specific drug delivery are decreased in active Crohn's disease. Dig Dis Sci 1995; 40: 2641-2646.
30. Ott SJ et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004; 53: 685-693.
31. Vargo D et al. Faecal bacterial flora in cancer of the colon. Gut 1980; 21: 701-705.
32. Gazzaniga A et al. Time-controlled oral delivery systems for colon targeting. Expert Opin Drug Deliv 2006; 3: 583-597.
33. Neurath MF et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995; 182: 1281-1290.
34. Heller F et al. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002; 17: 629-638.
35. Bodmeier R, Paerataku O. Mechanical properties of dry and wet cellulosic and acrylic films prepared from aqueous colloidal polymer dispersions used in the coating of solid dosage forms. Pharm Res 1994; 11: 882-888.
36. Nykanen P et al. Citric acid as excipient in multiple-unit enteric-coated tablets for targeting drugs on the colon. Int J Pharm 2001; 229: 155-162.
37. Van Den Mooter G et al. Characterization of colon-specific azo polymers: a study of the swelling properties and permeability of isolated polymers films. Int J Pharm 1994; 111: 127-136.
38. Blanchon S et al. Permeability of progesterone and a synthetic progestin through methacrylic films. Int J Pharm 1991; 72: 1-10.
39. He W et al. Study on colon-specific pectin/ethylcellulose film-coated 5-fluorouracil pellets in rats. Int J Pharm 2008; 348:35-45.
40. Flynn GL et al. Mass transport phenomena and models: theoretical concepts. J Pharm Sci 1974; 63: 479-509.
41. Mcconnell EL et al. An investigation into the digestion of chitosan (noncrosslinked and crosslinked) by human colonic bacteria. J Pharm Sci 2008; 97: 3820-3829.
42. Gliko-Kabir I et al. Phosphated crosslinked guar for colon-specific drug delivery. II. In vitro and in vivo evaluation. J Control Release 2000; 63: 129-134.
43. Haupt S et al. Luminal delivery and dosing considerations of local celecoxib administration to colorectal cancer. Eur J Pharm Sci 2006; 28: 204-211.
44. Okhamafe AO, York P. Studies of interaction phenomena in aqueous-based film coatings containing soluble additives using thermal analysis techniques. J Pharm Sci 1988; 77: 438-443.
45. Felton LA. Characterization of coating systems. AAPS PharmSciTech 2007; 8: E112.
46. Siew LF et al. The properties of amylose-ethylcellulose films cast from organic-based solvents as potential coatings for colonic drug delivery. Eur J Pharm Sci 2000; 11: 133-139.
47. He W et al. Selective drug delivery to the colon using pectin coated pellets. PDA J Pharm Sci Technol. (in press).
48. Hjärtstam J, Hjertberg T. Swelling of pellets coated with a composite film containing ethylcellulose and hydroxypropyl methylcellulose. Int J Pharm 1998; 161: 23-28.
49. Bodmeier R, Paeratakul O. Dry and wet strengths of polymeric films prepared from an aqueous colloidal polymer dispersion, Eudragit RS 30D. Int J Pharm 1993; 96: 129-138.
50. Parra DF et al. Mechanical properties and water vapor transmission in some blends of cassava starch edible films. Carbohydr Polym 2004; 58: 475-481.
51. Wang ZF et al. Effect of temperature and structure on the free volume and water vapor permeability in hydrophilic polyur-ethanes. J Membr Sci 2004; 241: 355-361.
52. Akhgari A et al. Permeability and swelling studies on free films containing inulin in combination with different polymethacry-lates aimed for colonic drug delivery. Eur J Pharm Sci 2006; 28: 307-314.
53. Cavalcanti OA et al. Polysaccharides as excipients for colon-specific coatings, permeability and swelling properties of casted films. Drug Dev Ind Pharm 2002; 28: 157-164.
54. Vervoort L et al. Inulin hydrogels. II. In vitro degradation study. Int J Pharm 1998; 172: 137-145.
55. Van Den Mooter G et al. In vivo evaluation of a colon-specific drug delivery system: an absorption study of theophylline from capsules coated with azo polymers in rats. Pharm Res 1995; 12: 244-247.
56. Leong CW et al. The formation of colonic digestible films of amylose and ethylcellulose from aqueous dispersions at temperatures below 37 degrees C. Eur J Pharm Biopharm 2002; 54: 291-297.
57. Langer RS, Peppas NA. Present and future applications of biomaterials in controlled drug delivery systems. Biomaterials 1981; 2: 201-214.
58. Rubinstein A. Approaches and opportunities in colon-specific drug delivery. Crit Rev Ther Drug Carrier Syst 1995; 12: 101-149.
59. Tarvainen M et al. Starch acetate-a novel film-forming polymer for pharmaceutical coatings. J Pharm Sci 2002; 91: 282-289.
60. Pellequer Y et al. Epithelial heparin delivery via microspheres mitigates experimental colitis in mice. J Pharmacol Exp Ther 2007; 321: 726-733.
61. Hovgaard L, Brøndsted H. Current applications of polysaccharides in colon targeting. Crit Rev Ther Drug Carrier Syst 1996; 8: 185-223.
62. Salyer A. Energy sources of major intestinal fermentative anaerobes. Am J Clin Nutr 1979; 32: 158-163.
63. Favier C et al. Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease. Dig Dis Sci 1997; 42: 817-822.
64. Salyers AA, Leedle JA. Human intestinal microflora in health and disease. In: Hentge DJ, ed. Carbohydrate Metabolism in the Human Colon. New York: Academic Press, 1983: 129-146.
65. Simon GL, Gorbach SL. Intestinal flora in health and disease. Gastroenterology 86: 1984; 174-193.
66. Stephen AM, Cummings JH. The microbial contribution to human faecal mass. J Med Microbiol 1980; 13: 45-56.
67. Hill MJ, Drasar BS. The normal colonic bacterial flora. Gut 1975; 16: 318-323.
68. Swidsinski A et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122: 44-54.
69. Linskens RK et al. The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol Suppl. 2001; 234: 29-40.
70. Ashford M, Fell JT. Targeting drugs to the colon: delivery systems for oral administration. J Drug Target 1994; 2: 241-257